Barcia Giulia, Rachid Myriam, Magen Maryse, Assouline Zahra, Koenig Michel, Funalot Benoit, Barnerias Christine, Rötig Agnès, Munnich Arnold, Bonnefont Jean-Paul, Steffann Julie
Université Paris Descartes - Sorbonne Paris Cité, Institut Imagine, INSERM UMR1163, Laboratoire des Maladies Mitochondriales, Paris, France; Service de Génétique, Groupe hospitalier Necker Enfants Malades, Assistance Publique -Hôpitaux de Paris, Paris, France.
Service de Génétique, Groupe hospitalier Necker Enfants Malades, Assistance Publique -Hôpitaux de Paris, Paris, France.
Eur J Med Genet. 2018 Aug;61(8):455-458. doi: 10.1016/j.ejmg.2018.03.004. Epub 2018 Mar 9.
Freidreich ataxia (FRDA) is the most common hereditary ataxia, nearly 98% of patients harbouring homozygous GAA expansions in intron 1 of the FXN gene (NM_000144.4). The remaining patients are compound heterozygous for an expansion and a point mutation or an exonic deletion. Molecular screening for FXN expansion is therefore focused on (GAA)n expansion analysis, commonly performed by triplet repeat primed PCR (PT-PCR). We report on an initial pitfall in the molecular characterization of a 15 year-old girl with Freidreich ataxia (FRDA) who carried a rare deletion in intron 1 of the FXN gene. Due to this deletion TP-PCR failed to amplify the GAA expansion. This exceptional configuration induced misinterpretation of the molecular defect in this patient, who was first reported as having no FXN expansion. NGS analysis of a panel of 212 genes involved in nuclear mitochondrial disorders further revealed an intragenic deletion encompassing exons 4-5 of the FXN gene. Modified TP-PCR analysis confirmed the presence of a classical (GAA)n expansion located in trans. This case points out the possible pitfalls in molecular diagnosis of FRDA in affected patients and their relatives: detection of the FXN expansion may be impaired by several non-pathological or pathological variants around the FXN (GAA)n repeat. We propose a new molecular strategy to accurately detect expansion by TP-PCR in FRDA patients.
弗里德赖希共济失调(FRDA)是最常见的遗传性共济失调,近98%的患者在FXN基因(NM_000144.4)第1内含子中存在纯合GAA重复扩增。其余患者为扩增与点突变或外显子缺失的复合杂合子。因此,FXN扩增的分子筛查主要集中于(GAA)n扩增分析,通常采用三联体重复引物PCR(PT-PCR)进行。我们报告了一名15岁弗里德赖希共济失调(FRDA)女孩分子特征鉴定过程中的一个初始陷阱,该女孩在FXN基因第1内含子中存在罕见缺失。由于该缺失,TP-PCR未能扩增出GAA重复扩增。这种特殊情况导致对该患者分子缺陷的误解,该患者最初被报告为无FXN扩增。对一组212个与核线粒体疾病相关基因的二代测序(NGS)分析进一步揭示了一个包含FXN基因第4至5外显子的基因内缺失。改良的TP-PCR分析证实了反式存在的经典(GAA)n扩增。该病例指出了在受影响患者及其亲属中进行FRDA分子诊断时可能存在的陷阱:FXN(GAA)n重复周围的几种非病理性或病理性变异可能会干扰FXN扩增的检测。我们提出了一种新的分子策略,以通过TP-PCR准确检测FRDA患者的扩增。